Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Izuma Nakayama
Observed name:
I. Nakayama
Institution:
National Cancer Center Hospital East
Observed institutions:
The Cancer Institute Hospital,
National Cancer Center Hospital East,
Japanese Foundation For Cancer Research
ORCID:
0000-0003-4987-1934
Observed ORCID:
0000-0003-4987-1934
OpenAlex ID:
A5035547838
690TiP HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
2024
·
T.B. Powles
, A.K. Bhatia
, et al.
·
Annals of Oncology
·
8
PDF
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
2026
·
Izuma Nakayama
, Min-Hee Ryu
, et al.
·
Journal of Clinical Oncology
·
5
1420P Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC)
2024
·
S. Sato
, S.L. Rhodes
, et al.
·
Annals of Oncology
·
5
Neutrophil‐Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo‐Immunotherapy
2026
·
Keita H. Nagaoka
, Hiroki Yamashita
, et al.
·
Cancer Science
·
3
An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203).
2026
·
Yu Aoki
, Izuma Nakayama
, et al.
·
Journal of Clinical Oncology
·
1
Whole-genome sequencing–based ultra-sensitive ctDNA molecular residual disease assessment in resectable gastric cancer: Results from MONSTAR-SCREEN-3.
2026
·
Etsuro Bando
, Masahiro Yura
, et al.
·
Journal of Clinical Oncology
·
1
Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.
2026
·
Izuma Nakayama
, Bernard Gaston Doger de Spéville
, et al.
·
Journal of Clinical Oncology
·
1
ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).
2026
·
Sung Hee Lim
, Izuma Nakayama
, et al.
·
Journal of Clinical Oncology
·
1
A cDC1 ‐ NK /T‐Malignant Cell Circuit Drives Immunogenic Remodeling Under PD ‐1 Blockade in Gastric Cancer
2026
·
Takuya Nakatsuru
, Hiroki Yamashita
, et al.
·
Cancer Science
·
1
Clinical management of perioperative FLOT for resectable gastric, gastroesophageal junction, or esophageal adenocarcinoma: Practical insights from a Japanese single-institute experience.
2026
·
Rika Uchino
, Mashiro Okunaka
, et al.
·
Journal of Clinical Oncology
·
1
527P Prognostic and therapeutic implications of EGFR expression in HER2-positive advanced gastric cancer
2026
·
T. Ogura
, I. Nakayama
, et al.
·
Annals of Oncology
PDF
An open label phase 2 study of total neoadjuvant therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally advanced gastroesophageal junction adenocarcinoma (EPOC2301).
2026
·
Kazuma Sato
, Izuma Nakayama
, et al.
·
Journal of Clinical Oncology
PDF
Clinical significance of c-Met expression in patients with advanced gastroesophageal adenocarcinoma.
2026
·
Akinori Kobayashi
, Tadayoshi Hashimoto
, et al.
·
Journal of Clinical Oncology
PDF
1465P Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
2024
·
T. Wakatsuki
, T. Mashima
, et al.
·
Annals of Oncology
PDF
Clinical Significance of CRP to Albumin Ratio in Nivolumab Therapy for Unresectable Esophageal Squamous Cell Carcinoma
2023
·
S. Maruyama
, A. Okamura
, et al.
·
Nihon Kikan Shokudoka Gakkai Kaiho
Show more works
View as search
Works count:
15
Citation count:
27
H-index:
3
I10-index:
Year
Topic
Type